Trial Profile
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Lumasiran (Primary)
- Indications Primary hyperoxaluria type 1
- Focus Registrational; Therapeutic Use
- Acronyms ILLUMINATE-A
- Sponsors Alnylam Pharmaceuticals
- 13 Feb 2024 Status changed from active, no longer recruiting to completed.
- 01 May 2023 36-month results presented at the 118th Annual Meeting of the American Urological Association.
- 06 Oct 2022 According to an Alnylam Pharmaceuticals media release, the USFDA has approved a label expansion for OXLUMO (lumasiran), indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate (UOx) and plasma oxalate (POx) levels in pediatric and adult patients. The approval is based on results of this trial.